Author: [AUTHOR] Published on 7/1/2019 12:00:00 AM
Eric Masson, PharmD, Vice President, Clinical Pharmacology & Pharmacometrics, Biogen, Inc., Cambridge, MA
Dr. Masson first learned of ASCPT during his post‐doc at St. Jude's Children's Research Hospital where his advisor, Dr. William Evans, encouraged him to apply and become a member. Since becoming a member, his favorite parts of ASCPT are the Annual Meeting, the journals, and the webinars. Last year, he joined the ASCPT Webinar Committee and believes that the Society's webinars are “a great way of disseminating the science across members from various disciplines, practices, and geography.” He looks forward to continuing on the Committee as a vice chair and to building a great series for 2019.
After 20‐plus years working in oncology, Dr. Masson is excited to have joined Biogen to build and lead a talented team of clinical pharmacologists. Biogen is a biotech company at the forefront of research with a mission of developing new medicines to treat neurologic disorders. He and his team utilized various drug modalities, such as small molecules, biologics, antisense oligonucleotides, and gene therapy, to treat neurologic and adjacent diseases, including Alzheimer's, Parkinson's, Multiple Sclerosis, Spinal Muscular Atrophy, Stroke, Epilepsy, Ophthalmology, and Amyotrophic Lateral Sclerosis. At the 2019 Annual Meeting, the unmet need and promise for medical breakthrough in these areas was highlighted in a talk by Dr. Richard Finkel. This talk about the development and approval of nusinersen, the first antisense oligonucleotide administered intrathecally for Spinal Muscular Atrophy, which has impacted several patients and their families really stuck with Dr. Masson.
Dr. Masson firmly believes that ASCPT is improving healthcare and pharmacotherapy for patients, including personalized medicine and outcome. He explains that “ASCPT is improving health care with better molecules, drug development plans, improved regulatory science, and quantitative and predictive science.”
Dr. Masson has been a member of ASCPT since 1997.